Uma nova disciplinha para o treinamento de formadores e educadores da area da didática das ciências experimentais

La creciente demanda de la sociedad por un estado saludable físico y psíquico obliga a reflexionar sobre programas formativos para desarrollar la competencia en alimentación (Cabello-Garrido, EspañaRamos y Blanco-López, 2016). Desde la Fundación Española del Corazón (FEC), se promueve que para una dieta cardiosaludable el saber qué comprar es clave para un corazón sano (Plaza-Celemín, 2015). Se aboga por una dieta equilibrada donde se apremia los alimentos ricos en hidratos de carbono incluyendo: patatas, legumbres, pan, arroz, pasta, cereales, verduras, hortalizas, frutas y frutos secos a razón de un porcentaje mayor del 50%. Los alimentos ricos en grasas con un porcentaje entre el 3035% eligiendo aceite de oliva virgen y aceite de girasol alto oleico como aceite de fritura. Y entorno al 10-15% de productos ricos en proteínas como lácteos y carnes como publica la prestigiosa revista JAMA (C.B. et al., 2012). Por ello el primer paso para conseguir una dieta equilibrada se inicia por saber qué comprar (Ordovas & Berciano, 2014), aprendiendo a comprar según el contenido nutricional sabiendo analizar el etiquetado los alimentos (García-Ortiz, 2015). La competencia alimentaria no sólo incluye el saber qué comprar en función de su etiquetado analizando las calorías, grasas saturadas, sal y azúcares sino en cómo comerlo y cocinarlo y propiciar el entorno adecuado para alimentarse de manera apropiada (Cabello-Garrido, España-Ramos y Blanco-López, 2016).Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech

La cardioeducación: una nueva disciplina en la educación infantil

La cardioeducación es una nueva disciplina que hemos creado desde el departamento de Didáctica de las ciencias experimentales y el Departamento de Fisiología Humana para dar formación a los maestros y maestras en formación del grado de Educación Infantil con el fin de mejorar su conocimiento en el tema . La enfermedad cardiovascular es la primera causa de muerte en el mundo y es fundamental generar disciplinas transversales que busquen la mejora en la formación de nuestro alumnado.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols